Febuxostat
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Febuxostat Product Information
Febuxostat is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Febuxostat. The product is supplied by Clearsynth under CAT No. CS-O-11648.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Febuxostat
CAS No.
144060-53-7
CAT No.
CS-O-11648
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C16H16N2O3S
Molecular Weight
316.37
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Febuxostat is supplied with detailed characterization data compliant with regulatory guideline. Febuxostat can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Febuxostat.
Overview
Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.
Synonyms
Febuxostat
Application Notes
Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.